Literature DB >> 17924645

Multiobjective long-term planning of biopharmaceutical manufacturing facilities.

K Lakhdar1, J Savery, L G Papageorgiou, S S Farid.   

Abstract

Biopharmaceutical companies with large portfolios of clinical and commercial products typically need to allocate production across several multiproduct facilities, including third party contract manufacturers. This poses several capacity planning challenges which are further complicated by the need to satisfy different stakeholders often with conflicting objectives. This work addresses the question of how a biopharmaceutical manufacturer can make better long-term capacity planning decisions given multiple strategic criteria such as cost, risk, customer service level, and capacity utilization targets. A long-term planning model that allows for multiple facilities and accounts for multiple objectives via goal programming is developed. An industrial case study based on a large scale biopharmaceutical manufacturer is used to illustrate the functionality of the model. A single objective model is used to identify how best to use existing capacity so as to maximize profits for different demand scenarios. Mitigating risk due to unforeseen circumstances by including a dual facility constraint is shown to be a reasonable strategy at base case demand levels but unacceptable if demands are 150% higher than expected. The capacity analysis identifies where existing capacity fails to meet demands given the constraints. A multiobjective model is used to demonstrate how key performance measures change given different decision making policies where different weights are assigned to cost, customer service level, and utilization targets. The analysis demonstrates that a high profit can still be achieved while meeting key targets more closely. The sensitivity of the optimal solution to different limits on the targets is illustrated.

Mesh:

Year:  2007        PMID: 17924645     DOI: 10.1021/bp0701362

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  4 in total

1.  Autologous CAR T-cell therapies supply chain: challenges and opportunities?

Authors:  Maria M Papathanasiou; Christos Stamatis; Matthew Lakelin; Suzanne Farid; Nigel Titchener-Hooker; Nilay Shah
Journal:  Cancer Gene Ther       Date:  2020-01-14       Impact factor: 5.987

2.  Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities.

Authors:  Cyrus C Siganporia; Soumitra Ghosh; Thomas Daszkowski; Lazaros G Papageorgiou; Suzanne S Farid
Journal:  Biotechnol Prog       Date:  2014-01-24

3.  Optimization-based framework for resin selection strategies in biopharmaceutical purification process development.

Authors:  Songsong Liu; Spyridon Gerontas; David Gruber; Richard Turner; Nigel J Titchener-Hooker; Lazaros G Papageorgiou
Journal:  Biotechnol Prog       Date:  2017-05-18

Review 4.  CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem.

Authors:  Hideyuki Kurata; Tetsuya Ishino; Yasuhiro Ohshima; Masafumi Yohda
Journal:  Front Bioeng Biotechnol       Date:  2022-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.